To determine the potential underlying mechanisms associated with HNSCC inhibition by dual IPI-549/anti-PD-L1 treatment, we investigated its impact on myeloid cell recruitment and activity. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.